Balyasny Asset Management LLC boosted its position in Laboratory Corporation of America Holdings (NYSE:LH) by 86.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,068 shares of the medical research company’s stock after buying an additional 38,492 shares during the period. Balyasny Asset Management LLC owned approximately 0.08% of Laboratory Corporation of America Holdings worth $12,804,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Laboratory Corporation of America Holdings by 2.3% in the second quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock valued at $1,597,181,000 after buying an additional 231,600 shares during the last quarter. BlackRock Inc. boosted its position in Laboratory Corporation of America Holdings by 3,602.5% in the 1st quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock worth $1,158,430,000 after purchasing an additional 7,856,297 shares in the last quarter. State Street Corp boosted its position in Laboratory Corporation of America Holdings by 2.4% in the 1st quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock worth $665,669,000 after purchasing an additional 109,170 shares in the last quarter. Boston Partners boosted its position in Laboratory Corporation of America Holdings by 4.8% in the 2nd quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock worth $707,560,000 after purchasing an additional 210,138 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in Laboratory Corporation of America Holdings by 2.0% in the 2nd quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock worth $415,693,000 after purchasing an additional 54,100 shares in the last quarter. Hedge funds and other institutional investors own 93.19% of the company’s stock.

Laboratory Corporation of America Holdings (LH) opened at 152.18 on Thursday. The company has a 50-day moving average price of $154.25 and a 200 day moving average price of $148.52. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $164.22. The firm has a market capitalization of $15.49 billion, a P/E ratio of 21.31 and a beta of 0.92.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.07. The firm had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. Laboratory Corporation of America Holdings’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.36 earnings per share. Analysts expect that Laboratory Corporation of America Holdings will post $9.53 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/balyasny-asset-management-llc-purchases-38492-shares-of-laboratory-corporation-of-america-holdings-lh.html.

Several equities research analysts have commented on the company. Craig Hallum restated a “buy” rating and issued a $179.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Thursday, July 27th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Barclays PLC upped their price objective on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. Jefferies Group LLC restated a “hold” rating and issued a $170.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Wednesday, September 13th. Finally, ValuEngine upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research report on Wednesday, September 6th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Laboratory Corporation of America Holdings has a consensus rating of “Buy” and a consensus target price of $165.82.

In related news, CEO David P. King sold 132,713 shares of Laboratory Corporation of America Holdings stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total transaction of $20,843,903.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lisa J. Uthgenannt sold 5,000 shares of Laboratory Corporation of America Holdings stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total value of $800,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 222,968 shares of company stock valued at $34,980,922. 0.90% of the stock is currently owned by insiders.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.